FDA approves bedaquiline as part of therapy for pulmonary tuberculosis

News
Article

Results confirmed that a bedaquiline-containing regimen offered a significant improvement in treatment outcomes compared to injectable-containing regimens.

FDA approves bedaquiline as part of therapy for pulmonary tuberculosis | Image Credit: © Calin - © Calin - stock.adobe.com.

FDA approves bedaquiline as part of therapy for pulmonary tuberculosis | Image Credit: © Calin - © Calin - stock.adobe.com.

The FDA has issued a traditional approval for bedaquiline (SIRTURO; Johnson & Johnson) to be a part of combination therapy for individuals aged 5 years and older with pulmonary tuberculosis (TB) because of Mycobacterium tuberculosis resistant to at least rifampicin and isoniazid.

According to a press release from Johnson & Johnson, label restrictions that were included when the medicine was granted accelerated approval in 2012 are now removed.

The decision was supported by data resulting from the phase 3, STREAM Stage 2 study (NCT02409290), a large-scale, randomized, multi-country, open-label study that evaluated safety and efficacy of an all-oral bedaquiline-containing regimen for treatment of MDR-TB. Results demonstrated that the regimen "offered a significant improvement in treatment outcomes compared to injectable-containing regimens," stated Johnson & Johnson in a press release.

Granted accelerated approval by the FDA in December 2012, a supplemental New Drug Application for bedaquiline was submitted to the FDA in August 2023 to support traditional approval.

According to Johnson & Johnson, bedaquiline should not be used for the treatment of latent infection because of Mycobacterium tuberculosis, drug-sensitive pulmonary or extra-pulmonary TB, or to treat infections caused by non-TB mycobacteria.

Reference:

Johnson & Johnson receives approval from US FDA and European Commission for SIRTURO (bedaquiline). Johnson & Johnson. Press release. July 2, 2024. Accessed July 3, 2024. https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-approval-from-u-s-fda-and-european-commission-for-sirturo-bedaquiline

Recent Videos
Brittany Bruggeman, MD
Octavio Ramilo
Octavio Ramilo, MD
Brittany Bruggeman, MD
Tina Tan, MD, FAAP, FIDSA, FPIDS
Tanya Altmann, MD, discusses the growing issue of childhood obesity in the United States and the benefits of new weight management medications.
Rana Hamdy, MD
Tina Tan, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.